Photo of Alex Bataller/LinkedIn
Feb 15, 2024, 18:42
Alex Bataller: Phase 1/2 trial results of oral decitabine/cedazuridine with venetoclax in higher risk MDS and CMML
Alex Bataller, Leukemia fellow at Leukemia Department, MD Anderson Cancer Center (Houston, Texas), shared a post on X/Twitter:
”Delighted to announce our newest publication in The Lancet Haematology of the phase 1/2 trial results of oral decitabine/cedazuridine with venetoclax in higher risk MDS and CMML.
This totally oral combination had an acceptable toxicity profile with an encouraging ORR of 95% and 49% of patients undergoing subsequent HSCT.”
Source: Alex Bataller/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19